At UCB, we aspire to be the patient-preferred biotech leader. Everything we do starts with a simple question: ‘How will this create value for people living with severe diseases?’
UCB’s patient value strategy aims to deliver, through a deep understanding of patient subpopulations, unique outcomes and the best patient experience to as many lives as possible within specific populations.
With more than 7500 people in approximately 40 countries, UCB generated revenue of EUR 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB)